GEA Process Engineering A/S - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GEA Process Engineering A/S

Improve drug properties and production with spray drying

Spray drying is a technique preferred by a growing number of pharmaceutical companies to produce better drugs. This ultra-fast and gentle drying technology offers unique possibilities of producing powders with advanced properties - even under aseptic conditions.

Several companies are already benefitting from the technology as an ‘enabling technology’ - to improve the performance of poorly soluble APIs by producing an amorphous solid dispersion, to obtain controlled release or taste-masking, or to produce advanced powders with specific properties.

GEA Process Engineering - the company behind GEA Niro spray drying technology - is the leading provider of spray drying technology to the pharmaceutical industry, and is one of the few companies that offer a full range of spray drying units and services to companies working with the develop-ment of spray dried pharmaceuticals and pharmaceutical grade products. Our portfolio covers the complete development cycle - from the initial proof of concept tests where only a few milliliters of material are available to full-scale production of clinical trial materials and commercial products under cGMP conditions. For better results on any scale, look to GEA Process Engineering.

Website: www.niro.com
E-mail: gea-niro.pharma@gea.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here